Search Within

Kimberly Leticia Loo

Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (6)
  2. Melanoma and Immunotherapeutics Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Melanoma Disease Management Team (5)
  5. GSK Faculty (4)
  6. Hematologic Malignancies, Division of (4)

More Groups

People
  1. Michael Postow (5)
  2. Allison Betof Warner (4)
  3. Jedd Wolchok (4)
  4. Katherine Panageas (3)
  5. Alexander Shoushtari (2)
  6. Hannah Kalvin (2)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (2)
Publications
  1. Journal of Clinical Oncology (2)
  2. Frontiers in Immunology (1)
  3. International Journal of Radiation Oncology, Biology, Physics (1)
  4. Pigment Cell & Melanoma Research (1)
  5. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Elsevier Inc. (1)
  3. Frontiers Media S.A. (1)
  4. Oxford University Press (1)
  5. Wiley Blackwell (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Characteristics of patients who survived more than 5 years after diagnosis of melanoma brain metastases
    Meeting Abstract

    Gui, C.; Wolchok, J. D.; Postow, M. A.; Betof Warner, A.; Loo, K.; Brennan, C. W.; Moss, N. S.; Tabar, V. S.; Beal, K.
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Melanoma-specific clinical outcomes of inpatient immune checkpoint blockade treatment
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Park, V.; Postow, M. A.
    The Oncologist (2022)

    Fulltext@MSK | Save
  • Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma
    Journal Article

    Loo, K.; Smithy, J. W.; Postow, M. A.; Betof Warner, A.
    Frontiers in Immunology (2022)

    Fulltext@MSK | Save
  • Disparities in the use of checkpoint inhibitors and CAR T-cell therapy: A systematic review
    Meeting Abstract

    Jutagir, D. R.; Espinosa, A.; Lopez, M.; Rasool, B.; Gomez, T.; Brown, A.; Frankel, C. A.; Loo, K.; Goldberg, J.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB)
    Meeting Abstract

    Loo, K.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save